Developer docs
API playgroundTry for free, no card

Search company profiles

TheraCell

Full company profile

uuid000e2fx

Namestring
TheraCell
Company typeenum
Private
Founded yearint
2008
Descriptiontext

TheraCell is a privately held biotechnology company, founded in 2008 and headquartered in Northridge, California, that develops two patented platform technologies for stereotactic transplantation of neurons and therapeutic cells into the brain. The company sits at the intersection of neuroscience, cell therapy, and neurosurgical device engineering, focused on enabling precise, minimally invasive delivery of neural cells into the central nervous system — an application aimed at neurological indications where conventional small-molecule and biologic therapeutics have demonstrated limited efficacy. The platform-centric technology posture is consistent with a business model anchored to intellectual property development, potential research collaborations, and downstream therapeutic or licensing optionality rather than direct product commercialization.

The organization is structured as a small, research-intensive operation of 1-10 employees led by Bradley Patt (Chairman & Chief Executive Officer), Andrew J. Carter (CTO), and Nelson Scarborough (Chief Scientific Officer), indicating a technically driven leadership profile. To date, TheraCell has funded operations through two modest equity rounds recorded in the source data — a $1,344,000 raise on 2009-09-03 and a $75,000 raise on 2015-03-17 — totaling approximately $1.42M in disclosed capital across more than fifteen years. The combination of a multi-year gap in financing activity, micro-cap raises, an absence of disclosed revenue, and no documented commercial partnerships, license deals, or product milestones establishes an early-stage, pre-revenue operating profile oriented toward sustaining preclinical research and intellectual property protection.

Short descriptiontext

TheraCell is a privately held Northridge, California-based biotechnology company founded in 2008 that develops two patented platform technologies enabling stereotactic transplantation of neurons and therapeutic cells into the brain.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNorthridge, United States
HQ citystring
Northridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neurosurgical cell delivery, stereotactic transplantation, neuron transplantation devices, therapeutic cell delivery, regenerative neurosurgery
Industry2 codes
PRIMARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAACAL
Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Neurosurgical Cell Delivery Platforms
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Autologous Therapy Products
TypeHardware Sales
Description

Sale of Magellan and Precise autologous concentration systems and associated kits for creating PRP, cBMA, and PPP therapies

istobiologics.com
2Allograft Products
TypeHardware Sales
Description

Sale of allograft-derived products including Influx product line (ProteiOS, Fibrant, SPARC, PLUS, Sponge) derived from donor tissue

istobiologics.com
3Synthetic Bone Grafts
TypeHardware Sales
Description

Sale of InQu biosynthetic bone graft products for spinal fusion and orthopedic procedures

istobiologics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
Pricing details1 tier
1Quote-based pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Contact sales for pricing on all products including Magellan, Influx, InQu, and Precise systems

istobiologics.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

TheraCell develops two patented platform technologies that facilitate stereotactic transplantation of neurons and therapeutic cells into the brain. The company focuses on neurosurgical instrumentation and delivery platforms designed to enable precise cell-based therapies for central nervous system indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • InQu biosynthetic bone graft outperforms fusion rates of ICBG (iliac crest bone graft)
Product and service2 records
1Patented Stereotactic Neuron Transplantation Platform
CategoryNeurosurgical Delivery Device
2Patented Therapeutic Cell Delivery Platform
CategoryNeurosurgical Delivery Device
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Physicians and surgeons worldwide partner with Isto Biologics to use orthobiologic products and provide clinical feedback for product development and improvement

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Medical product distributors partner with Isto Biologics to market and distribute orthobiologic products including Magellan, Influx, and InQu to healthcare facilities

3Hospital Administrators
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Hospital administrators evaluate and procure Isto Biologics products for institutional use in orthopedic and spinal procedures

istobiologics.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Medical researchers partner with Isto Biologics for clinical research support and studies involving orthobiologic products

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Maker of the Neuromate stereotactic neurosurgical robot used for DBS, stereo-EEG, and cell therapy implantation. Directly comparable as an established device-side peer addressing the same stereotactic delivery workflow TheraCell's platform targets.

TypeBroad incumbent
Description

Established surgical navigation and stereotactic neurosurgery platform whose systems are routinely used for precision intracranial delivery. Comparable as a potential competitor or partner for TheraCell's stereotactic delivery platform, with broader neurosurgery footprint and established hospital channels.

TypeDirect peer
Description

Developer of autologous iPSC-derived dopamine neuron cell therapies for Parkinson's disease that require stereotactic surgical delivery into the striatum. Comparable because it represents the most direct addressable market for TheraCell's stereotactic neuron transplantation platform.

TypeEmerging player
Description

Clinical-stage developer of neural cell therapies (Q-Cells) for CNS conditions including transverse myelitis, ALS, and spinal cord injury. Comparable to TheraCell because it is a smaller, focused neural cell therapy developer whose commercial path depends on precise CNS delivery.

TypeDirect peer
Description

Clinical-stage developer of autologous cell therapies (NurOwn) for neurodegenerative diseases including ALS and MS. Highly comparable to TheraCell because both operate in the CNS cell therapy delivery space and require stereotactic or surgical cell implantation infrastructure to administer their therapies.

TypeBroad incumbent
Description

Well-capitalized cell and gene therapy platform developing hypoimmune allogeneic cell therapies across oncology, type 1 diabetes, and CNS indications. Comparable to TheraCell as a potential strategic acquirer or partner of stereotactic delivery technology for its CNS programs.

TypeEmerging player
Description

Allogeneic T-cell and cell therapy developer with CNS and oncology indications that rely on precise cell delivery methods. Comparable as a modality-platform peer whose pipeline economics depend on the kind of stereotactic and surgical delivery infrastructure TheraCell provides.

8Notch Therapeutics
TypeEmerging player
Description

Developer of iPSC-derived engineered immune and stem cell therapies with an emerging CNS focus. Comparable as a smaller, modality-platform peer whose cell products would require the kind of stereotactic delivery technology TheraCell develops.

TypeDirect peer
Description

Clinical-stage allogeneic cell therapy developer with programs in spinal cord injury (OPC1) and neurodegenerative retinal disease, both requiring precise surgical cell delivery. Comparable to TheraCell as a peer targeting the same intersection of cell therapy and CNS surgical delivery.

TypeDirect peer
Description

Bayer-owned pluripotent stem cell therapy developer focused on Parkinson's disease and other CNS indications using surgical cell implantation into the brain. Directly comparable as both a CNS cell therapy developer and a likely customer for stereotactic delivery platforms like TheraCell's.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks3 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TheraCell

Neurosurgical Cell Delivery Platformstheracellinc.com

TheraCell is a privately held Northridge, California-based biotechnology company founded in 2008 that develops two patented platform technologies enabling stereotactic transplantation of neurons and therapeutic cells into the brain.

What TheraCell does

TheraCell is a privately held biotechnology company, founded in 2008 and headquartered in Northridge, California, that develops two patented platform technologies for stereotactic transplantation of neurons and therapeutic cells into the brain. The company sits at the intersection of neuroscience, cell therapy, and neurosurgical device engineering, focused on enabling precise, minimally invasive delivery of neural cells into the central nervous system — an application aimed at neurological indications where conventional small-molecule and biologic therapeutics have demonstrated limited efficacy. The platform-centric technology posture is consistent with a business model anchored to intellectual property development, potential research collaborations, and downstream therapeutic or licensing optionality rather than direct product commercialization.

The organization is structured as a small, research-intensive operation of 1-10 employees led by Bradley Patt (Chairman & Chief Executive Officer), Andrew J. Carter (CTO), and Nelson Scarborough (Chief Scientific Officer), indicating a technically driven leadership profile. To date, TheraCell has funded operations through two modest equity rounds recorded in the source data — a $1,344,000 raise on 2009-09-03 and a $75,000 raise on 2015-03-17 — totaling approximately $1.42M in disclosed capital across more than fifteen years. The combination of a multi-year gap in financing activity, micro-cap raises, an absence of disclosed revenue, and no documented commercial partnerships, license deals, or product milestones establishes an early-stage, pre-revenue operating profile oriented toward sustaining preclinical research and intellectual property protection.

TheraCell firmographics

Firmographics
Name
TheraCell
Website
https://theracellinc.com
Company type
Private
Founded year
2008
Headcount range
1–10 employees
Short description
TheraCell is a privately held Northridge, California-based biotechnology company founded in 2008 that develops two patented platform technologies enabling stereotactic transplantation of neurons and therapeutic cells into the brain.
Ownership category
akta.pro rank

TheraCell industry classification

Industry
Product category
Neurosurgical Cell Delivery Platforms
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAACAL
Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Neurosurgical cell delivery
  • Stereotactic transplantation
  • Neuron transplantation devices
  • Therapeutic cell delivery
  • Regenerative neurosurgery

Where TheraCell is headquartered

Location

Headquarters

HQ city
Northridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

TheraCell business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Autologous Therapy Products: Sale of Magellan and Precise autologous concentration systems and associated kits for creating PRP, cBMA, and PPP therapies
  2. Allograft Products: Sale of allograft-derived products including Influx product line (ProteiOS, Fibrant, SPARC, PLUS, Sponge) derived from donor tissue
  3. Synthetic Bone Grafts: Sale of InQu biosynthetic bone graft products for spinal fusion and orthopedic procedures

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based pricing

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

TheraCell product offering

Product offering

Core offering

TheraCell develops two patented platform technologies that facilitate stereotactic transplantation of neurons and therapeutic cells into the brain. The company focuses on neurosurgical instrumentation and delivery platforms designed to enable precise cell-based therapies for central nervous system indications.

Differentiator

Problem solved

Functional benefit

Products and services

  • Patented Stereotactic Neuron Transplantation Platform
  • Patented Therapeutic Cell Delivery Platform

Quantifiable outcome

  • InQu biosynthetic bone graft outperforms fusion rates of ICBG (iliac crest bone graft)

Companies that use TheraCell

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles1 record

TheraCell technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

TheraCell partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • PhysicianscoreStrategic or Co-development PartnerPhysicians and surgeons worldwide partner with Isto Biologics to use orthobiologic products and provide clinical feedback for product development and improvement
  • DistributorscoreChannel Partner/ Reseller/ DistributorMedical product distributors partner with Isto Biologics to market and distribute orthobiologic products including Magellan, Influx, and InQu to healthcare facilities
  • Hospital AdministratorsminorChannel Partner/ Reseller/ DistributorHospital administrators evaluate and procure Isto Biologics products for institutional use in orthopedic and spinal procedures
  • ResearchersminorStrategic or Co-development PartnerMedical researchers partner with Isto Biologics for clinical research support and studies involving orthobiologic products

Scale indicators2 records

Recent moves2 records

Expansion highlights1 record

TheraCell competitors and assessment

Company assessment

Direct peers

  • Renishaw (Neuromate / neurosurgery): Maker of the Neuromate stereotactic neurosurgical robot used for DBS, stereo-EEG, and cell therapy implantation. Directly comparable as an established device-side peer addressing the same stereotactic delivery workflow TheraCell's platform targets.
  • Aspen Neuroscience: Developer of autologous iPSC-derived dopamine neuron cell therapies for Parkinson's disease that require stereotactic surgical delivery into the striatum. Comparable because it represents the most direct addressable market for TheraCell's stereotactic neuron transplantation platform.
  • BrainStorm Cell Therapeutics: Clinical-stage developer of autologous cell therapies (NurOwn) for neurodegenerative diseases including ALS and MS. Highly comparable to TheraCell because both operate in the CNS cell therapy delivery space and require stereotactic or surgical cell implantation infrastructure to administer their therapies.
  • Lineage Cell Therapeutics: Clinical-stage allogeneic cell therapy developer with programs in spinal cord injury (OPC1) and neurodegenerative retinal disease, both requiring precise surgical cell delivery. Comparable to TheraCell as a peer targeting the same intersection of cell therapy and CNS surgical delivery.
  • BlueRock Therapeutics: Bayer-owned pluripotent stem cell therapy developer focused on Parkinson's disease and other CNS indications using surgical cell implantation into the brain. Directly comparable as both a CNS cell therapy developer and a likely customer for stereotactic delivery platforms like TheraCell's.

Broad incumbents

  • Brainlab: Established surgical navigation and stereotactic neurosurgery platform whose systems are routinely used for precision intracranial delivery. Comparable as a potential competitor or partner for TheraCell's stereotactic delivery platform, with broader neurosurgery footprint and established hospital channels.
  • Sana Biotechnology: Well-capitalized cell and gene therapy platform developing hypoimmune allogeneic cell therapies across oncology, type 1 diabetes, and CNS indications. Comparable to TheraCell as a potential strategic acquirer or partner of stereotactic delivery technology for its CNS programs.

Emerging players

  • Q Therapeutics: Clinical-stage developer of neural cell therapies (Q-Cells) for CNS conditions including transverse myelitis, ALS, and spinal cord injury. Comparable to TheraCell because it is a smaller, focused neural cell therapy developer whose commercial path depends on precise CNS delivery.
  • Atara Biotherapeutics: Allogeneic T-cell and cell therapy developer with CNS and oncology indications that rely on precise cell delivery methods. Comparable as a modality-platform peer whose pipeline economics depend on the kind of stereotactic and surgical delivery infrastructure TheraCell provides.
  • Notch Therapeutics: Developer of iPSC-derived engineered immune and stem cell therapies with an emerging CNS focus. Comparable as a smaller, modality-platform peer whose cell products would require the kind of stereotactic delivery technology TheraCell develops.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks3 records

Key highlights4 records

Customer concentration

TheraCell social profiles

Digital presence

TheraCell financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TheraCell leadership team

Management profile

Number of profiles

Profiles1 record

TheraCell funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TheraCell M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TheraCell

What does TheraCell do?

TheraCell develops two patented platform technologies that facilitate stereotactic transplantation of neurons and therapeutic cells into the brain. The company focuses on neurosurgical instrumentation and delivery platforms designed to enable precise cell-based therapies for central nervous system indications.

When was TheraCell founded?

TheraCell was founded in 2008. It employs 1 to 10 people.

Where is TheraCell based?

TheraCell is headquartered in Northridge, United States, in the North America region.

How does TheraCell make money?

Three revenue lines are on record. Autologous Therapy Products are the primary driver. The others are allograft Products and synthetic Bone Grafts.

Who are TheraCell's main competitors?

Direct peers on record are Renishaw (Neuromate / neurosurgery), Aspen Neuroscience, BrainStorm Cell Therapeutics, Lineage Cell Therapeutics and BlueRock Therapeutics. Broad incumbents are Brainlab and Sana Biotechnology. Emerging players are Q Therapeutics, Atara Biotherapeutics and Notch Therapeutics.

Does TheraCell have an API?

No public API is recorded for TheraCell.

What industry is TheraCell in?

TheraCell's product category is Neurosurgical Cell Delivery Platforms. Its primary akta.pro industry code is HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods), with a secondary code of HLAAACAL, Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery). Its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
eeNews EuropeTheiaCel tackles LED flicker exterior camerasOmnivision unveiled its first automotive image sensor using TheiaCel technology to address LED flicker, the OX08D10 8MP CMOS sensor. It uses a 2.1-micron pixel with LOFIC capacitors and DCG HDR, offering 115dB dynamic range and 50% smaller size. Samples are available now, with mass production in the second half of 2024.IFTTTNano Dotz teams with Greek co TheraCellDotz Nano's share price rose 9% after it signed a contract with Greek firm TheraCell Labs, expected to generate at least $5 million in revenue in the first year. The collaboration will use Dotz Nano's carbon-based materials to mark bioprocessing consumables and develop a standard for tagging patient-derived cells, with TheraCell paying 5% of sales revenue.PR NewswireTHERACELL ACQUIRED BY ISTO BIOLOGICSIsto Biologics has acquired TheraCell, Inc., a developer of allograft solutions and the TheraFuze DBF technology. This transaction expands Isto's portfolio of orthopedic grafts and integrates TheraCell's patented technologies into its Influx line to enhance surgical care in spine and sports medicine.PR NewswireTheraCell Announces First Surgical Use Of TheraFuze DBF® Fiber Bullets™ In An Interbody TLIF CageTheraCell Inc. announced the completion of the first surgical procedure using its TheraFuze DBF® Fiber Bullets™, a demineralized bone fiber product designed for delivery into expandable cages and spinal fusion applications. The procedure was performed by Dr. Neel Anand at Cedars Sinai Medical Center as an L3-L4 PSF with interbody TLIF, during which multiple Fiber Bullets™ were placed anterior and posterior to the implant to achieve complete endplate-to-endplate contact. The product is now commercially available in the United States as part of TheraCell's comprehensive portfolio of procedure-specific allograft solutions.PR NewswireTheraCell Announces Delivery Of Over 25,000 Of Its Licensed Bone Fiber GraftsTheraCell Inc. announced that its licensee partners have delivered over 25,000 of its licensed demineralized bone fiber grafts, achieving an annual end-customer sales rate approaching $30 million. The company has licensed its TheraFuze DBF technology to AlloSource for the U.S. market and Australian Biotechnologies for Australia and New Zealand, while also launching an expanded portfolio of procedure-specific graft forms.PR NewswireTheraCell Announces Royalty Milestone From LicensingTheraCell Inc. announced that its royalty income from licensing its demineralized bone fiber technology surpassed a $1.0 million annual run rate as of September 30, 2020. This milestone represents a 55% increase compared to the same period in the previous year, driven by consistent quarter-over-quarter growth. The company highlighted ongoing success with licensees AlloSource and Australian Biotechnologies while launching new products in its TheraFuze DBF portfolio.PR NewswireTheraCell and AlloSource Announce Issuance of Patent for Bone Fiber TechnologyTheraCell announced that the United States Patent and Trademark Office will issue the company a patent for its demineralized bone fiber (DBF™) technology, expanding its intellectual property portfolio in the regenerative medicine space. The patented DBF technology is incorporated into two AlloSource products — AlloFuse Cortical Fibers and AlloFuse Fiber Boats — which consist of 100 percent demineralized cortical bone and are used in spine and orthopedic fusion procedures. TheraCell and AlloSource highlighted the technology's handling characteristics and noted an industry shift toward fiber-based allografts as a driver for broader product development.